HC Wainwright & Co. Assumes Tarsus Pharmaceuticals at Buy, Announces Price Target of $72
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Matthew Caufield assumes Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and announces Price Target of $72.
HC Wainwright & Co. analyst Matthew Caufield assumes Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy rating and announces Price Target of $72.